Compumedics appoints Syed Husain to lead Somfit® US pharmacy and consumer program
Compumedics Limited (ASX: CMP) has appointed Mr Syed Husain, Managing Partner of Red Brook Advisors, as strategic adviser to lead its Somfit® US pharmacy and consumer program. The announcement was made on 6 November 2026.
The program is evaluating partnership, licensing, distribution and strategic investment opportunities for Somfit® and the NEXUS 360® platform with US pharmacy, consumer-health and related healthcare groups. It is the first of the Board’s dedicated deal-maker appointments across its five value-realisation programs.
Key points from the appointment:
- Appointee: Mr Syed Husain, Managing Partner, Red Brook Advisors
- Role: strategic adviser leading the Somfit® US pharmacy and consumer program
- Products in scope: Somfit® and the NEXUS 360® platform
- Opportunity types: partnership, licensing, distribution and strategic investment
When big ASX news breaks, our subscribers know first
Who is Syed Husain? A pharmacy and healthcare M&A background
Mr Husain was previously Head of Corporate Development and M&A at a Fortune 5 US healthcare company. His pharmacy and corporate development background is directly relevant to a program targeting US pharmacy and consumer-health groups.
His credentials, as set out in the announcement:
- Registered pharmacist and healthcare M&A executive with more than 30 years’ experience
- Almost 20 years at a Fortune 5 US healthcare company, rising to Head of Corporate Development and M&A
- Later founded the healthcare and pharmacy practice at a boutique Wall Street investment bank
- Has led Red Brook Advisors since 2023
What is a strategic adviser and why does it matter?
A strategic adviser helps a company identify, structure and negotiate deals such as partnerships, licensing arrangements and distribution agreements. For investors, commercial deals of this kind could build value without relying solely on a company’s own sales footprint in a large market such as the US, although no outcome is assured.
A value-realisation approach that avoids issuing new shares
The Board describes its approach as designed to realise value for shareholders through partnerships or strategic investment rather than by issuing new shares. For shareholders, the key takeaway is that the approach is framed around limiting dilution, which is the reduction in each existing holder’s ownership share when new shares are issued.
The adviser role sits alongside Compumedics’ internal US build-out, where a US Chief Commercial Officer with a large-scale medtech P&L background is strengthening the sleep and IDTF commercial teams around Somfit®.
The announcement states one forward-looking event:
- Further appointments: the Board expects to make two to three further strategic investment or investment banking appointments by the end of the March 2027 quarter.
Compumedics is a global medical device company that develops, manufactures and commercialises diagnostic technology for sleep, brain and ultrasonic blood flow monitoring applications. It owns Neuroscan (USA) and DWL Elektronische Systeme GmbH (Germany). Executive Chairman Dr. David Burton founded the company in 1987, and it listed on the ASX in 2000.
Don’t Miss the Next Healthcare Breakout
Join 20,000+ investors getting FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis and the full announcement. Click the “Free Alerts” button at Big News Blast to get market-moving news the moment it breaks and stay ahead of the market.